Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license.

Charlene Vos

2019-05-01 09:27:00 Wed ET

Apple settles its 2-year intellectual property lawsuit with Qualcomm by agreeing to a multi-year patent license with royalty payments to the microchip maker. As part of this settlement, Apple and Qualcomm need to forego all legal actions worldwide, and the former continues to buy microchips from the latter. With a $2 increase in its latest EPS in early-2019, Qualcomm experiences a 23% share price boost well above $65, and its market capitalization surges by $14.5 billion to more than $83 billion. Qualcomm thus enjoys its best share price performance since 1999. In stark contrast, Apple faces a 3% share price decline, and also the Qualcomm microchip archrival Intel experiences a moderate share price dip.

During the fiscal year from 2018 to early-2019, Apple employs Intel microchips for the iPhone XS and XR production. Apple needs to surpass this strenuous patent settlement with Qualcomm to focus on 5G networks and revolutionary iPhone and iPad functions. With vital access to Intel and Qualcomm microchips, Apple designs 5G iPhones sooner than the late-2020 release date that numerous stock analysts anticipate. The surprise lawsuit settlement represents a *pyrrhic victory* for Apple as Qualcomm inflicts a hard toll on the smartphone bellwether.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Netflix has an unsustainable business model in the meantime.

Becky Berkman

2019-05-02 13:30:00 Thursday ET

Netflix has an unsustainable business model in the meantime.

Netflix has an unsustainable business model in the meantime. Netflix maintains a small premium membership fee of $9-$14 per month for its unique collection

+See More

This infographic visualization summarizes the key habits and investment styles of highly successful entrepreneurs.

Chanel Holden

2017-12-19 09:39:00 Tuesday ET

This infographic visualization summarizes the key habits and investment styles of highly successful entrepreneurs.

From Oprah Winfrey​ to Bill Gates​, this infographic visualization summarizes the key habits and investment styles of highly successful entrepreneurs:

+See More

Top 4 U.S. richest people are self-made billionaires: Gates, Buffet, Bloomberg, and Zuckerberg.

Dan Rochefort

2017-08-01 09:40:00 Tuesday ET

Top 4 U.S. richest people are self-made billionaires: Gates, Buffet, Bloomberg, and Zuckerberg.

In American states, all of the Top 4 richest people are self-made billionaires: Bill Gates in Washington, Warren Buffett in Nebraska, Michael Bloomberg in N

+See More

Blackrock asset research director Andrew Ang shares his economic insights into fundamental factors for global asset management.

Apple Boston

2019-07-29 11:33:00 Monday ET

Blackrock asset research director Andrew Ang shares his economic insights into fundamental factors for global asset management.

Blackrock asset research director Andrew Ang shares his economic insights into fundamental factors for global asset management. As Ang indicates in an inter

+See More

President Trump hails and touts America's new high real GDP economic growth in mid-2018.

Daisy Harvey

2018-07-25 11:41:00 Wednesday ET

President Trump hails and touts America's new high real GDP economic growth in mid-2018.

President Trump hails and touts America's new high real GDP economic growth in 2018Q2. The U.S. is now a $20+ trillion economy, and America hits this mi

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More